glp-1 receptor agonist antipsychotic weight gain study Efficacy and Safety of Agonists for the Management of Antipsychotic-Induced Frontiers | The Burden of
Description
10.1016/j.nefro.2022.07.008 [DOI] [PubMed] [Google Scholar] 27
Implication of the MAPK signalling pathway in the pathogenesis of diabetic nephropathy
Leech, C
For many patients who experience fatigue when starting GLP-1 therapy, symptoms often improve as the body adapts to the medication
